Nasdaq ikna.

IKNA Price $1.40 Fair Value Price N/A Market Cap $67.56M 52 Week Low $1.02 52 Week High $7.64 P/E -0.86x P/B 0.43x P/S 13.48x PEG N/A Dividend Yield N/A …

Nasdaq ikna. Things To Know About Nasdaq ikna.

BOSTON--(BUSINESS WIRE)--May 13, 2021-- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced financial results for the quarter ended March 31, 2021.BOSTON, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...The stock of Ikena Oncology Inc (NASDAQ: IKNA) has decreased by -8.11 when compared to last closing price of 1.48.Despite this, the company has seen a loss of -66.99% in its stock price over the last five trading days. Zacks Investment Research reported 2023-06-20 that Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to ...Here’s What You Need To Know. By JESSICA GRANT. Sep 21, 2022. As the world’s largest furniture retailer for nearly 15 years, investors want to own shares of IKEA stock. Table of Contents show. The Swedish furniture company is known worldwide for its do-it-yourself furniture, meatballs, and iconic stores. The company’s growth, popularity ...Dec 25, 2021 · See All Market Activity. News + Insights. CLOSE

IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ...BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment ...

May 12, 2022 · BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Nasdaq | IKNA U.S.: Nasdaq Ikena Oncology Inc. Watch list Set a price target alert After Hours Last Updated: Nov 9, 2023 6:00 p.m. EST Delayed quote $ 1.2500 -0.08 -6.02% …Ikena Oncology Inc (NASDAQ:IKNA) showed a performance of -46.11% in past 30-days. Number of shares sold short was 1.28 million shares which calculate 16.64 days to cover the short interests. Wall Street analysts have assigned a consensus price target of $8.33 to the stock, which implies a rise of 78.39% to its current value.Biogen Inc. (NASDAQ:BIIB) announced negative topline results from the Phase 3 STAR study of timrepigene emparvovec, an investigational gene therapy for the potential treatment of choroideremia.19 oct. 2022 ... (Nasdaq: IKNA, “Ikena”), una compañía de oncología específica que forja un nuevo territorio en el tratamiento del cáncer dirigido por el ...

Every investor in Ikena Oncology, Inc. (NASDAQ:IKNA) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies ...

Advancement across Company’s pipeline towards regulatory and data milestonesBOSTON, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology ...

BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Ikena Oncology, Inc. : News, information and stories for Ikena Oncology, Inc. | Nasdaq: IKNA | NasdaqBOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, announced ...Webull offers Ikena Oncology Inc stock information, including NASDAQ: IKNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKNA stock news, and many more online research tools to help you make informed decisions.Ikena Oncology, Inc. (NASDAQ:IKNA) Achilles Therapeutics plc (NASDAQ:ACHL) Related Link: Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates . Photo by Thought Catalog on Unsplash.Experience · BioSight Ltd., an Israeli company, in its merger with Ayala Pharmaceuticals, Inc. · Ikena Oncology Inc.'s (NASDAQ: IKNA) acquisition of Pionyr ...

Previous investments include Icosavax (NASDAQ: ICVX), Kymera Therapeutics (NASDAQ ... (NASDAQ: IKNA), Synthekine and Vanqua Bio. Previous to Omega Funds, Paulina ...Nov 7, 2023 · Nov. 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena,” “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today ... May 18, 2023 · IKNA has a market cap of $253mn and a cash balance of $157mn. Research and development expenses were $64.3 million for the year ended December 31, 2022 and general and administrative expenses were ... BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...30 minutes. No description. Ikena™ is redefining the targeted oncology landscape and envisions a world in which every cancer patient has a cure. We develop therapies that target the underlying mechanisms driving cancer survival and growth.BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Webull offers Ikena Oncology Inc stock information, including NASDAQ: IKNA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IKNA stock news, and many more online research tools to help you make informed decisions.

BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that ...Forgot password ? Remember

29 avr. 2021 ... Switch to the basic mobile site. Facebook wordmark. Video.When the Nasdaq is said to be "down," that usually means that the Nasdaq Composite Index, an investment index comprised of some of the largest companies on the Nasdaq stock exchange, is losing value. This can be an indication that the broad...Selected Balance Sheet Items: September 30, 2023 December 31, 2022: Cash and cash equivalents $ 121,277 $ 59,919 Marketable securities $ 75,656Nov 24, 2023 · Ikena Oncology (NASDAQ:IKNA) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment?We will contrast the two companies based on the strength of their media sentiment, analyst recommendations, dividends, community ranking, earnings, profitability, valuation, institutional ownership and risk. Company shares further detail on the differentiators of IK-930, a TEAD-paralog selective inhibitor. BOSTON, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a ...Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology, Inc.Is General American Investors Company, Inc. (NYSE:GAM) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the ...4.2100. +0.3500. +9.07%. BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer ...BOSTON, Oct. 26, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...

Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology ...

Fintel reports that on May 24, 2023, HC Wainwright & Co. reiterated coverage of Ikena Oncology (NASDAQ:IKNA) with a Buy recommendation. Analyst Price Forecast Suggests 210.16% Upside. As of May 11 ...

Osiris Therapeutics (OTCMKTS:OSIR – Get Free Report) and Ikena Oncology (NASDAQ:IKNA – Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, valuation, dividends, institutional ownership, earnings, risk and analyst recommendations. Earnings and Valuation This table compares ...The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on Thursday, November 9, 2023.The analyst firm set a price target for 11.00 expecting IKNA to rise ...(NASDAQ: IKNA) Ikena Oncology currently has 48,258,111 outstanding shares. With Ikena Oncology stock trading at $1.40 per share, the total value of Ikena Oncology stock (market capitalization) is $67.56M.Ikena acquired all of Pionyr’s assets, including approximately $43 million in net cash, in exchange for shares of IKNA stock, in a combination of common stock and non-voting convertible ...Take Ikena Oncology (NASDAQ: IKNA) for instance. All in all, the company just announced today that the Food and Drug Administration (FDA) has granted a Fast Track designation for IK-930.Nov 30, 2023 · (NASDAQ: IKNA) Ikena Oncology currently has 48,258,111 outstanding shares. With Ikena Oncology stock trading at $1.40 per share, the total value of Ikena Oncology stock (market capitalization) is $67.56M. Fiscal Q3 2023 ended 9/30/23. Fiscal Q3 2023 ended 9/30/23. Get the latest Ikena Oncology Inc (IKNA) real-time quote, historical performance, charts, and other financial …The latest price target for . Ikena Oncology (NASDAQ: IKNA) was reported by HC Wainwright & Co. on Thursday, November 9, 2023.The analyst firm set a price target for 11.00 expecting IKNA to rise ... Find the latest Ikena Oncology Inc (IKNA) discussion and analysis from iHub's community of investors ... NASDAQ · Add Alert · Follow. 1. 1.71. 0.00 (0.00%). Quote ...Find the latest news headlines from Ikena Oncology, Inc. Common Stock (IKNA) at Nasdaq.com.Dec 17, 2021 · He focuses on private company investments and fundraising for the firm. Mr. Draetta currently serves on the board of Chord Therapeutics and is Chief Financial Officer of Omega Alpha SPAC (NASDAQ ...

Webull offers Ikena Oncology (IKNA) historical stock prices, in-depth market analysis, NASDAQ: IKNA real-time stock quote data, in-depth charts.Nasdaq Fund Secondaries; Featured Solutions Nasdaq's IPO Process; ETF Listings; Nasdaq-100 Index Options; Derivatives AcademyBOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ...Instagram:https://instagram. walmart stock dividendsstock options trading demo accountaquaponics weediphone 14 pro sold out Jun 22, 2022 · BOSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced ... farmland etfcigna plus dental plans Ikena Oncology, Inc. (NASDAQ:IKNA) is a Boston, Massachusetts-based company with a strong pipeline. Ikena Oncology, Inc. (NASDAQ:IKNA) went public in 2021. In November last year, Ikena Oncology, Inc.Gainers Celcuity Inc. (NASDAQ:CELC) shares climbed 50.9% to close at $21.60 on Friday after the company announced a worldwide licensing agreemen... insider stock trades Source: Kantar Media. View the latest Ikena Oncology Inc. (IKNA) stock price, news, historical charts, analyst ratings and financial information from WSJ.Ikena Oncology Inc (NASDAQ:IKNA) 4.46 Delayed Data As of Nov 03 +0.40 / +9.85% Today’s Change 1.94 Today ||| 52-Week Range 7.64 +67.67% Year-to-Date Quote Profile News Charts Forecasts...BOSTON, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company navigating new territory in patient-directed cancer treatment, announced ...